Google
SKYE — SKYE BIOSCIENCE, INC. COMMON STOCK (Healthcare >> Biotechnology)
SKYE FAQ
What is SKYE's ROE?
SKYE BIOSCIENCE, INC. COMMON STOCK reports a Return on Equity (ROE) of -636.18%.
What is SKYE's dividend yield?
SKYE BIOSCIENCE, INC. COMMON STOCK offers a dividend yield of 0.00%.
What is SKYE's Deepscope Quality Score?
Deepscope rates SKYE's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy SKYE?
Deepscope's AI Timing Score for SKYE is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does SKYE belong to?
SKYE BIOSCIENCE, INC. COMMON STOCK is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 0.75
Price
-0.02
(-2.48%)
Day Change
|
|
|---|
SKYE, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Negative growth of ROE in the last year.
ROE is decreasing significantly
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 80 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.75 |
| PBV / Sector |
2.86 / 4.71
|
| Earning Per Share | -1.67 |
| PE / Sector |
N/A / 17.58
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
0.15 M
GREAT
|
| Average 1W Daily Value |
0.15 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-10 09:43:42 |
| Symbol | SKYE |
| Name | SKYE BIOSCIENCE, INC. COMMON STOCK |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 35.14 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 25.77 / 8,889.42 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 11250 El Camino Real, San Diego, CA, United States, 92130
Phone: 858 410 0266
Website: https://skyebioscience.com
Sector: Healthcare >> Biotechnology
Description: Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
